RecruitingPHASE2, PHASE3NCT05749822

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Xijing Hospital of Digestive Diseases
Principal Investigator: Ying Han
Xijing Hospital, Air Force Military Medical Universit
Intervention: Fenofibrate 200mg(drug)
Enrollment: 104 target
Eligibility: 18-75 years · All sexes
Timeline: 2023 – 2027

Study locations (12)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Henan Provincial People's Hospital, Zhengzhou, Henan, China
Xiangya Hospital Central South University, Changsha, Hunan, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Xijing Hospital, Xi'an, Shaanxi, China
Yan'an University Affiliated Hospital, Yan’an, Shaanxi, China
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Tianjin Third Central Hospital, Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Tianjin Medical University General Hospital, Tianjin, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05749822 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials